We are live on ! Find out more
JSPR icon

Jasper Therapeutics

52 hedge funds and large institutions have $83.5M invested in Jasper Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

18% more capital inflows, than outflows

Capital inflows: $18.1M | Capital outflows: $15.3M

2.46% more ownership

Funds ownership: 81.77% → 84.23% (+2.5%)

2% more funds holding

Funds holding: 51 → 52 (+1)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
52
Holders Change
+1
Holders Change %
+1.96%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
11
Reduced
11
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

JSPR Hedge Fund Activity: Q1 2021 in Review

52 of the 5,709 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2021, worth a combined $83.5M — up 2% from $81.9M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new JSPR positions and 8 closed out — a net gain of 2 holders — while 11 added to existing stakes and 11 trimmed.

The largest buyer was Shaolin Capital Management, adding an estimated $3.56M. The largest seller was P. Schoenfeld Asset Management (PSAM), exiting entirely with an estimated $4.76M sold.

  • 52 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2021, up from 51 in Q4 2020.
  • Funds reported $83.5M of Jasper Therapeutics stock for Q1 2021, up 2% quarter-over-quarter.
  • 10 funds opened new Jasper Therapeutics positions in Q1 2021 and 8 closed out, a net change of +2 holders.
  • The largest Jasper Therapeutics buyer in Q1 2021 was Shaolin Capital Management, an estimated $3.56M added.
  • The largest Jasper Therapeutics seller in Q1 2021 was P. Schoenfeld Asset Management (PSAM), an estimated $4.76M sold.

Based on aggregated 13F filings for Q1 2021.